ATE382051T1 - Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit - Google Patents
Prodrugs von pharmazeutika mit erhöhter bioverfügbarheitInfo
- Publication number
- ATE382051T1 ATE382051T1 AT96919361T AT96919361T ATE382051T1 AT E382051 T1 ATE382051 T1 AT E382051T1 AT 96919361 T AT96919361 T AT 96919361T AT 96919361 T AT96919361 T AT 96919361T AT E382051 T1 ATE382051 T1 AT E382051T1
- Authority
- AT
- Austria
- Prior art keywords
- increased bioavailability
- prodrugs
- lipid prodrugs
- compositions
- pharmaceutical
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 239000000651 prodrug Substances 0.000 title abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
- C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/487,081 US7517858B1 (en) | 1995-06-07 | 1995-06-07 | Prodrugs of pharmaceuticals with improved bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE382051T1 true ATE382051T1 (de) | 2008-01-15 |
Family
ID=23934330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96919361T ATE382051T1 (de) | 1995-06-07 | 1996-06-07 | Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7517858B1 (enExample) |
| EP (1) | EP0837630B1 (enExample) |
| JP (1) | JP4301571B2 (enExample) |
| AT (1) | ATE382051T1 (enExample) |
| AU (1) | AU711774B2 (enExample) |
| CA (1) | CA2223989C (enExample) |
| DE (1) | DE69637381T2 (enExample) |
| ES (1) | ES2299178T3 (enExample) |
| WO (1) | WO1996039831A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9603726D0 (sv) * | 1996-10-11 | 1996-10-11 | Astra Ab | Novel compounds |
| US6410328B1 (en) * | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| WO1999039741A2 (en) * | 1998-02-03 | 1999-08-12 | Inex Pharmaceuticals Corporation | Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| IL131887A0 (en) * | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| KR20020073494A (ko) * | 1999-12-29 | 2002-09-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 약물내성 인체 면역결핍 바이러스 감염의 치료 |
| EP1460082A1 (en) * | 2003-03-19 | 2004-09-22 | Heidelberg Pharma Holding GmbH | Phospholipid esters of clofarabine derivatives |
| DE602005012155D1 (de) * | 2004-11-03 | 2009-02-12 | Liplasome Pharma As | Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid-derivaten und ihre therapeutische verwendung |
| CA2586363A1 (en) | 2004-11-15 | 2006-05-26 | Ceptyr, Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| ES2401285T3 (es) | 2004-12-16 | 2013-04-18 | The Regents Of The University Of California | Fármacos con el pulmón como diana |
| EP2004236A2 (en) * | 2006-03-23 | 2008-12-24 | Liplasome Pharma A/S | Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis |
| US7749983B2 (en) * | 2006-05-03 | 2010-07-06 | Chimerix, Inc. | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates |
| US8741966B2 (en) * | 2007-11-09 | 2014-06-03 | Pronova Biopharma Norge As | Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| EP2234623A4 (en) * | 2007-12-27 | 2012-03-28 | Epiphany Biosciences | ANTIVIRAL CONNECTIONS |
| EP2278963A4 (en) * | 2008-01-16 | 2014-09-17 | Anwar Rayan | TAXOL DERIVATIVES AND CLOSELY RELATED COMPOUNDS |
| EP2147910A1 (en) * | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Novel lipid compounds |
| JP5843755B2 (ja) | 2009-05-08 | 2016-01-13 | プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ | 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸 |
| US8884027B2 (en) | 2010-10-22 | 2014-11-11 | University Of Rochester | Melampomagnolide B derivatives as antileukemic and cytotoxic agents |
| NZ610705A (en) | 2010-11-05 | 2014-10-31 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| AU2014222389B2 (en) | 2013-02-28 | 2018-11-29 | Pronova Biopharma Norge As | A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| SMT201800538T1 (it) | 2013-03-15 | 2019-01-11 | Univ California | Diesteri di fosfonato nucleosidico aciclico |
| DK3116511T3 (da) | 2014-03-14 | 2020-11-23 | Alltech Inc | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf |
| HRP20220651T1 (hr) | 2014-09-15 | 2022-08-19 | The Regents Of The University Of California | Nukleotidni analozi |
| ES2855299T3 (es) | 2014-11-26 | 2021-09-23 | Vascular Biogenics Ltd | Lípidos oxidados y tratamiento o prevención de la fibrosis |
| US9771385B2 (en) * | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| GEP20217282B (en) | 2015-03-06 | 2021-08-10 | Atea Pharmaceuticals Inc | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| US20180104201A1 (en) | 2015-04-28 | 2018-04-19 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis |
| WO2017048252A1 (en) | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| US10377782B2 (en) | 2015-09-15 | 2019-08-13 | The Regents Of The University Of California | Nucleotide analogs |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| PT3720431T (pt) | 2017-12-06 | 2024-12-05 | Basf As | Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica |
| CA3131977C (en) * | 2019-03-22 | 2022-04-26 | Integrated Nanotherapeutics Inc. | Lipid conjugate prepared from scaffold moiety |
| CA3152013A1 (en) | 2019-08-22 | 2021-02-25 | Emory University | Nucleoside prodrugs and uses related thereto |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| MX2023002233A (es) | 2020-08-24 | 2023-03-15 | Gilead Sciences Inc | Compuestos fosfolipidos y usos de estos. |
| TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| JP2025526212A (ja) | 2022-07-21 | 2025-08-13 | アンティバ バイオサイエンシズ インコーポレイテッド | Ｈｐｖ感染症及びｈｐｖ誘発性新生物の治療用の組成物及び剤形 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7607496L (sv) | 1976-07-01 | 1978-01-02 | Astra Laekemedel Ab | Sett for bekempning av virusinfektioner |
| CA1140049A (en) | 1977-12-22 | 1983-01-25 | Dke J.E. Helgstran | Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid |
| DE3374837D1 (en) * | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| JPS61152694A (ja) * | 1984-12-27 | 1986-07-11 | Toyama Chem Co Ltd | 新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩 |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US5072032A (en) | 1989-06-21 | 1991-12-10 | Mckenna Charles E | Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| DE4111105A1 (de) * | 1991-04-05 | 1992-10-08 | Max Planck Gesellschaft | Neue erucyl-, brassidyl- und nervonylderivate |
| DE4226279A1 (de) | 1992-08-08 | 1994-02-10 | Boehringer Mannheim Gmbh | Liponucleotide von Seco-Nucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
| US5512671A (en) | 1993-02-16 | 1996-04-30 | Wake Forest University | Ether lipid-nucleoside covalent conjugates |
| US5484911A (en) * | 1993-04-01 | 1996-01-16 | Health Research, Inc. | Nucleoside 5'-diphosphate conjugates of ether lipids |
-
1995
- 1995-06-07 US US08/487,081 patent/US7517858B1/en not_active Expired - Fee Related
-
1996
- 1996-06-07 EP EP96919361A patent/EP0837630B1/en not_active Expired - Lifetime
- 1996-06-07 ES ES96919361T patent/ES2299178T3/es not_active Expired - Lifetime
- 1996-06-07 DE DE69637381T patent/DE69637381T2/de not_active Expired - Lifetime
- 1996-06-07 CA CA2223989A patent/CA2223989C/en not_active Expired - Lifetime
- 1996-06-07 JP JP50218097A patent/JP4301571B2/ja not_active Expired - Fee Related
- 1996-06-07 WO PCT/US1996/010054 patent/WO1996039831A1/en not_active Ceased
- 1996-06-07 AU AU61717/96A patent/AU711774B2/en not_active Expired
- 1996-06-07 AT AT96919361T patent/ATE382051T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US7517858B1 (en) | 2009-04-14 |
| EP0837630A1 (en) | 1998-04-29 |
| CA2223989A1 (en) | 1996-12-19 |
| WO1996039831A1 (en) | 1996-12-19 |
| EP0837630B1 (en) | 2007-12-26 |
| DE69637381D1 (de) | 2008-02-07 |
| DE69637381T2 (de) | 2008-12-11 |
| AU711774B2 (en) | 1999-10-21 |
| AU6171796A (en) | 1996-12-30 |
| JPH11512078A (ja) | 1999-10-19 |
| JP4301571B2 (ja) | 2009-07-22 |
| CA2223989C (en) | 2010-11-23 |
| ES2299178T3 (es) | 2008-05-16 |
| EP0837630A4 (en) | 1998-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69637381D1 (de) | Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit | |
| DE69604653D1 (de) | Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen | |
| NO953278D0 (no) | Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette | |
| ES2145774T3 (es) | Derivados de adenosina que tienen actividad agonista en a2. | |
| CY1113856T1 (el) | Διεργασια για την παραγωγη φαρμακοτεχνικων μορφων τριοξειδιου του αρσενικου | |
| ATE146674T1 (de) | Pharmazeutische zusammensetzung zur rektalen verabreichung von wirkstoffen mit topischer medizinischer wirkung im dickdarmniveau | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| ATE260926T1 (de) | Antivirale prodrugs | |
| FR2708608B1 (fr) | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. | |
| MX9203808A (es) | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. | |
| EP0738152A4 (en) | USE OF 2-HYDROXY-5-PHENYLAZOBOIC ACID DERIVATIVES AS ACTIVE SUBSTANCES FOR CHEMOPREVENTION AND CHEMOTHERAPY OF COLON CANCER | |
| FR2708606B1 (fr) | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. | |
| FR2764889B1 (fr) | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant | |
| ES2061688T3 (es) | Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion. | |
| MX9601994A (es) | Profarmacos de derivados de paclitaxel. | |
| MX9102701A (es) | Derivados de 2-acilamido de 3,4-dihidro-3-oxo-quinoxalina que tienen actividad farmaceutica. | |
| TR199700711T1 (xx) | Ciltten ge�erek v�cuda giren form�lasyon. | |
| BR9807936A (pt) | Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação | |
| FI101377B1 (fi) | Menetelmä N-alkyloitujen 1,4-dihydropyridiiniyhdisteiden valmistamiseksi | |
| EP0584034A3 (en) | Conjugates of cytotoxic drugs for the treatment of neoplastic diseases. | |
| FR2712289B1 (fr) | Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent. | |
| IT8323058A0 (it) | Derivati di 2,5-piperazindione biologicamente attivi, processi per la loro preparazione e composizioni farmaceutiche che licontengono. | |
| DE69610085D1 (de) | Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| FR2705094B1 (fr) | Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent. | |
| FR2705097B1 (fr) | Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |